The latest health & wellness articles from TheMurrow. In-depth analysis and reporting on the topics that matter.
June 30 isn’t a patient stop-date—it’s the close of an FDA public-comment window that could squeeze industrial compounding (503B) even as patient-specific compounding (503A) remains narrower, but not gone.
OTC continuous glucose monitors put medical-looking numbers in wellness apps—without the clinical context that makes them meaningful. A single 140 mg/dL can feel like a verdict when it’s often just physiology.
June 29, 2026 is being misread as a patient “stop date,” but it’s a procedural FDA comment deadline. The bigger danger is synchronized panic—especially after the 2025 shortage wind-down already tightened the rules.
OTC CGMs turned glucose into a consumer score—and “spikes” into a designed event, not a universal medical fact. The trick: app-defined thresholds and proprietary algorithms can make normal post-meal rises feel like failure.
Microplastics headlines are outrunning the standards that make those numbers comparable. The gap between “detected” and “meaningful measurement” is where detox products sell certainty.
The CDC’s 2026 measles surge is mostly an outbreak story—clusters, not a uniform national wave. The real confusion: 6–11 month MMR guidance that sounds like a new schedule, but isn’t.
OTC clearance turned CGMs into a retail wellness gadget—but it also widened the gap between measurement and meaning. The stream of “spikes” looks authoritative; in healthy people, context is the real data.
FDA’s April 30, 2026 proposal aims at the legal pathway that made API-based compounded GLP‑1s viable. If “clinical need” fails, access can shrink even without a dramatic raid or immediate ban.
The FDA is giving consumer wearables more room to make low-risk wellness claims—while drawing a hard line around blood pressure estimates. That boundary explains the whiplash patients feel and the caution clinicians keep repeating.
The peptide boom is being sold as “the next GLP‑1,” but one label cue—**research**—often reveals a workaround, not a regulated medicine supply chain.
Foundayo’s convenience is real—but Lilly’s own materials hide the most disruptive detail in plain sight: “Card expires and savings end on 12/31/2026.” If you don’t plan for that date up front, your treatment plan may collapse on a calendar, not in a clinic.
As FDA enforcement tightens, “copycat” access doesn’t disappear—it morphs into euphemisms, additives, and quieter sourcing changes. The danger isn’t only counterfeits; it’s ambiguity you can’t audit once it’s in the vial.
The FDA’s “resolved” label is national policy—not a guarantee at your pharmacy counter. Price, insurance gatekeeping, and telehealth convenience keep compounded vials in motion, even as enforcement tightens.
The Nancy case isn’t a referendum on the cap you twist off at lunch—it’s about alleged contamination at the source, tied to historic bottle dumps. Meanwhile, the plastic many consumers fear often enters later, during bottling and packaging.
The FDA’s rare, high-volume warning-letter burst targets a specific internet-era problem: marketing that makes compounded GLP‑1s feel indistinguishable from Ozempic, Wegovy, Mounjaro, or Zepbound—right at the moment patients decide to inject.
A 2026 peer‑reviewed study sent three identical NIST stool samples to seven direct‑to‑consumer microbiome testing services—and got meaningfully different results. If the input is the same but the “truth” changes, the instability isn’t your gut—it’s the measurement.
The FDA just fired 30 warning letters at telehealth brands selling compounded GLP‑1s with “same as” vibes and brand-forward sourcing blur. With shortages over, the loophole-era language is becoming the liability—and patients will feel the whiplash first.
The FDA ended the national shortage listing for Ozempic and Wegovy—but the vial-and-syringe semaglutide market didn’t disappear. It adapted, and regulators are signaling they’re done indulging the workaround.
OTC CGMs made glucose a consumer metric—but the line you’re watching is delayed, averaged, and easy to moralize. The biggest “spikes” are where interpretation is least reliable.
Creatine has gone from shaker-bottle staple to candy-like wellness accessory—especially for women. But the category’s simplest mantra (“just take 5 grams”) collides with gummy serving sizes, uneven women-specific evidence, and real-world adherence.